| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ENDRA Life Sciences Inc.$5.27
-0.34 (-6.06%)
F 2Pipeline Score MedTech · Clinical
Market Cap
6.93 M
EPS
-8.15
P/E Ratio
-
Value Trade
64.67 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
776.41 K
Operating CF
-1.12 M
Total Assets
3.44 M
Total Liabilities
1.65 M
Equity
1.79 M
D/E Ratio
12,345
-4.55 %
Week
7.06 %
1 Month
41.45 %
3 Month
-2.33 %
6 Month
-99.99 %
5 Year
-100 %
All Time
Cash Data
Cash Position
356.46 K
Monthly Burn
373.00 K
Runway
0 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
26.75 K
52 Week Range
2.92 - 11.96
% held by Insiders
42.14 %
% held by Institutions
7.06 %
Enterprise Value
7.04 M
Total Shares
1.24 M
Short %
5.77 %
Float Shares
1.17 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 877 of 912)
Percentile RankENDRA Life Sciences Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TAEUS Liver | steatotic liver disease | — | 2025-12-04 | critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%; high Positive Predictive Value (PPV); high Negative Predictive Value (NPV); 40 subjects with BMI ranging from 21 to 47; less than $200 Read More | ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use Read More | |
TAEUS Liver | steatotic liver disease | — | 2025-12-04 | critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%; high Positive Predictive Value (PPV); high Negative Predictive Value (NPV); 40 subjects with BMI ranging from 21 to 47; less than $200 Read More | ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use Read More | |
TAEUS Liver | steatotic liver disease | — | 2025-12-04 | critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%; high Positive Predictive Value (PPV); high Negative Predictive Value (NPV); 40 subjects with BMI ranging from 21 to 47; less than $200 Read More | ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NDRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NDRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NDRA▼ -8.9%on this news
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes has announced a proposed merger of Noble Africa with ENDRA Life Sciences, alongside a concurrent private placement financing of approximately $50 million. This merger aims to enhance the capabilities and market presence of both companies. Further details on the merger's implications and the financing structure have yet to be disclosed.
Read more →NDRA▲ +7.1%on this news
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences has reported its financial results for the first quarter of 2026. The company also provided a business update, although specific details about the results or updates were not disclosed in the article. The overall sentiment remains neutral due to the lack of detailed information.
Read more →NDRAENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
ENDRA Life Sciences has reported successful multi-site validation of its TAEUS® liver device, showcasing MRI-like accuracy and reproducibility in liver imaging. This validation is a significant step forward for the company, enhancing the credibility of the device in clinical settings. The results indicate a promising future for the TAEUS® technology in liver diagnostics.
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ENDRA Life Sciences reported its financial results for Q4 and full year 2025, highlighting significant clinical advancements with its TAEUS Liver technology. The company has initiated a review of strategic alternatives to enhance shareholder value while maintaining focus on its operational initiatives. Despite a reduction in operating expenses, ENDRA continues to face net losses, raising concerns about its financial sustainability.
Read more →NDRA▲ +8.4%on this news· ran to +35% by day 3
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ENDRA Life Sciences has begun evaluating strategic alternatives to maximize shareholder value. The Board of Directors is considering various options, including mergers and collaborations, while continuing to focus on its operational initiatives. The company has engaged financial and legal advisors to assist in this process, although no specific timeline has been set for its completion.
Read more →NDRAENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
ENDRA Life Sciences announced positive results from a clinical study of its TAEUS Liver device, demonstrating high consistency in measurements crucial for monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The device achieved a high reliability score, indicating its potential to deliver MRI-level results at a lower cost, which is vital for clinicians and pharmaceutical companies. This innovation could significantly improve patient care and monitoring.
Read more →NDRA▼ -7.7%on this news
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
ENDRA Life Sciences announced promising results from its TAEUS Liver device feasibility study, demonstrating that its thermo-acoustic fat fraction measurement closely aligns with the MRI-PDFF standard at critical liver fat thresholds. This positions TAEUS as a low-cost, effective tool for monitoring steatotic liver disease, potentially transforming the landscape for MASLD/MASH drug development. The study highlights TAEUS's ability to identify patients for clinical trials and therapy decisions efficiently.
Read more →NDRA▼ -5.9%on this news
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings Company Officially Launches Digital Asset Treasury Strategy Focused on
ENDRA Life Sciences Inc. has closed a private placement worth up to $14.4 million, which includes an initial $4.9 million and potential future proceeds from warrant exercises. Concurrently, the company launched its digital asset treasury strategy, investing $3 million in HYPE tokens. This strategy aims to enhance shareholder value through active yield-enhancement techniques in decentralized finance (DeFi). Despite the optimistic outlook, the company faces risks, including regulatory uncertainties and limited experience in the cryptocurrency sector.
Read more →NDRARecent Financial Results Below is a summary of certain preliminary estimates regarding our financial results for the quarter ended
The preliminary financial results for NDRA indicate a challenging quarter ending June 30, 2025. The company expects no revenue for this quarter, similar to the previous year. Although the loss from operations has decreased to approximately $1.3 million from $2.2 million, the total assets and working capital remain low, raising concerns about financial sustainability.
Read more →NDRAENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results ANN ARBOR, Mich. (
ENDRA Life Sciences recently provided a business update along with its first quarter 2025 financial results. The company is pivoting towards addressing metabolic diseases, specifically through the development of a low-cost, point-of-care diagnostic device for liver fat detection. Within its new strategy, ENDRA aims to improve early diagnosis, reduce healthcare costs, and has also reported a significant reduction in its operating expenses. However, the company faces challenges related to regulatory compliance and capital acquisition for continued operations.
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update ANN ARBOR, Mich. (
ENDRA Life Sciences reported its financial results for the fourth quarter and full year 2024, highlighting significant advances in the development of its TAEUS Liver device. The company refocused its strategies to improve regulatory processes and commenced a new multicenter clinical study involving major evaluation sites. Despite increased operating expenses and a higher net loss compared to 2023 due to one-time charges, ENDRA achieved notable reductions in cash burn through operational efficiencies. The revamped regulatory strategy is aimed at supporting a successful De Novo submission to the FDA.
Read more →NDRAENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement ANN ARBOR, Mich. (
ENDRA Life Sciences has announced that it has regained compliance with the Nasdaq minimum bid price requirement, as confirmed by the Nasdaq Listing Qualifications Department. The compliance allows ENDRA to focus on its transformational business strategies, which were discussed in a recent conference call. The company is known for its innovative technology, Thermo Acoustic Enhanced UltraSound (TAEUS), aimed at addressing the challenges related to assessing liver fat content and monitoring liver diseases.
Read more →NDRA▼ -14.2%on this news
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update Company accelerated enrollment in global multisite pilot study and significantly reduced operating expenses while refocusing
ENDRA Life Sciences reported its third quarter financial results, highlighting key developments in its Thermo Acoustic Enhanced UltraSound (TAEUS) technology. The company successfully accelerated subject recruitment for ongoing clinical evaluations and significantly lowered operating expenses by 54%. New AI-driven features for the TAEUS platform were developed, and the company expanded its intellectual property portfolio. Despite a net loss of $2.4 million in the quarter, the company remains focused on generating clinical data to support its FDA regulatory filing efforts.
Read more →NDRA▼ -19.6%on this news· ran to -32% by day 3
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. received an extension from Nasdaq until November 20, 2024, to comply with a minimum bid price requirement necessary for continued listing. The company needs to demonstrate a closing bid price of at least $1.00 per share for 10 consecutive trading days. The extension comes amid significant activity, as 91% of Series B Warrants have been exercised recently. ENDRA's TAEUS technology is recognized for its potential in non-invasive tissue assessment, particularly for fatty liver disease.
Read more →NDRAENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. reported its financial results for the second quarter of 2024, highlighting significant advancements in regulatory and clinical activities. The company successfully met with the FDA to discuss the TAEUS technology and initiated pilot clinical trials in North America and Europe. Additionally, ENDRA expanded its intellectual property portfolio, adding five new patents. Financially, the company raised $8 million through a public offering and reduced operating expenses by $3.1 million compared to the previous year.
Read more →NDRA▼ -22.5%on this news· ran to -83% by day 3
ENDRA Life Sciences Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on
ENDRA Life Sciences has announced a 1-for-50 reverse stock split, effective August 20, 2024, to comply with Nasdaq's minimum bid price requirements. As a result, the number of outstanding shares will decrease significantly from approximately 72.4 million to about 1.4 million. The split is intended to stabilize the stock price and help the company maintain its Nasdaq listing. Stockholders will automatically have their shares adjusted without needing to take further action, and details about the split can be found in the company's regulatory filings.
Read more →NDRAENDRA Life Sciences Announces Leadership Changes Board Member Alexander Tokman appointed as acting CEO bringing 24+ years of global commercial leadership experience Two additional industry veterans join in key roles incl
ENDRA Life Sciences has appointed Alexander Tokman as acting CEO following the departure of Francois Michelon. Tokman, who has over 24 years of commercial leadership experience, will spearhead efforts to advance the company’s Thermo Acoustic Enhanced UltraSound (TAEUS) technology. Additionally, Ziad Rouag and Richard Jacroux have been welcomed to the management team, focusing on regulatory affairs and financial strategies, respectively. The company is emphasizing its commitment to bringing innovative diagnostic solutions to the market.
Read more →NDRAENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. announced the pricing of a public offering expected to generate gross proceeds of approximately $8 million. The offering includes 61.5 million shares of common stock and associated warrants, with each share priced at $0.13. The funds raised will be allocated to working capital and general corporate purposes. The offering is anticipated to close on June 5, 2024, pending the satisfaction of customary closing conditions.
Read more →NDRAENDRA Provides Update Following In-person Meeting with FDA Increases clarity for ENDRA on regulatory path forward for TAEUS ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. has provided an update following a productive pre-submission meeting with the FDA about its TAEUS liver device. The meeting discussed the clinical trial design necessary for the U.S. De Novo filing, during which ENDRA showcased the TAEUS procedure. The feedback received is viewed as constructive, allowing ENDRA to refine its pivotal clinical study protocol and statistical plan ahead of submission. Management emphasizes the importance of engagement with the FDA to ensure alignment for their future studies.
Read more →NDRAENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences reported its financial results for Q1 2024, highlighting its first installation of the TAEUS system in the UK at King's College Hospital for clinical evaluation. The company has submitted a comprehensive package to the FDA as it works towards regulatory approval of its liver assessment technology. Additionally, ENDRA has expanded its intellectual property portfolio to 80 patents, indicating growth in its technological capabilities. However, the company reported a net loss of $2.8 million and a decrease in cash reserves to $1.1 million.
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences reported its financial results for Q4 and the full year of 2023, highlighting significant developments in its TAEUS technology. The company installed its first TAEUS system at King's College Hospital in the UK for clinical evaluation against MRI standards. Additionally, it is actively communicating with the FDA regarding its De Novo request for TAEUS liver system, indicating a commitment to regulatory compliance. ENDRA's intellectual property has expanded with new patents, and it has received an ICD-10-CM code that will facilitate improved diagnostics for NAFLD.
Read more →NDRAENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences (NASDAQ: NDRA) announced its third quarter 2023 financial results and provided a business update, highlighting positive developments in their Thermo Acoustic Enhanced UltraSound (TAEUS) system. The company shared promising clinical data at a recent summit and showcased their technology at various industry conferences. Additionally, ENDRA achieved an important milestone with the issuance of 70 patents globally, and their De Novo request to the FDA progressed to substantive review. The overall outlook remains positive as the management anticipates future growth and commercial orders for TAEUS.
Read more →NDRAENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences announced its financial results for Q2 2023, highlighting a pivotal De Novo submission for its TAEUS liver system to the FDA. The submission is supported by strong clinical data that shows TAEUS effectively assesses liver fat compared to MRI standards. The company participated in key European conferences to elevate the system's profile and secured additional patents to bolster its intellectual property. With recent funding, ENDRA is positioned to support upcoming business milestones and expand its market presence.
Read more →NDRAENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to
ENDRA Life Sciences Inc. announced that its 2023 Annual Meeting of Stockholders was adjourned due to the absence of a required quorum. The meeting is rescheduled for July 25, 2023, allowing stockholders additional time to cast their votes on the proposals presented in the proxy statement. Despite the adjournment, the company is actively soliciting participation from stockholders who have yet to vote, emphasizing the importance of their involvement.
Read more →NDRAENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Inc. has reported its financial results for the first quarter of 2023 and provided key updates on its TAEUS system. The company successfully completed data collection necessary for their FDA De Novo submission for a liver device aimed at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). The TAEUS system's capabilities were highlighted at various clinical conferences, and seven new patents were issued to protect its technology. Additionally, ENDRA strengthened its financial position by raising $4.5 million, extending its cash runway for future regulatory and commercialization efforts.
Read more →NDRAENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering ANN ARBOR, Mich. (
ENDRA Life Sciences has announced the pricing of an upsized public offering of $4.5 million, including 3,750,000 shares of common stock and warrants. Each two shares sold comes with a warrant, potentially increasing capital for general corporate purposes, including product development and regulatory submissions. The expected closing date for this offering is May 2, 2023, with Newbridge Securities Corporation acting as the sole underwriter. The funds from this public offering are key to advancing ENDRA's innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to revolutionize liver disease diagnostics.
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences has reported its financial results for Q4 2022 and the full year, revealing over 100 scans performed with its TAEUS system. The company is preparing to submit a De Novo request to the FDA for its liver device aimed at assessing NAFLD. ENDRA renewed its partnership with GE HealthCare, enhancing its market presence. Despite showing progress, the company experienced increased operating costs, leading to greater net losses compared to 2021.
Read more →NDRAENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (November 14, 2022) -ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (
Read more →NDRAENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (August 15, 2022) - ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (
Read more →NDRAENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
PRESS RELEASE DATED MAY 12, 2022, FURNISHED HEREWITH. endra_ex991.htm EXHIBIT 99.1 ENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (May 12, 2022) - ENDRA Life
Read more →NDRAENDRA Life Sciences Raises $8.7 Million in Gross Proceeds Through its At-The-Market Facility Extends cash runway into 2023 ANN ARBOR, Mich. (
PRESS RELEASE DATED APRIL 21, 2022, FURNISHED HEREWITH. endra_ex991.htm EXHIBIT 99.1 ENDRA Life Sciences Raises $8.7 Million in Gross Proceeds Through its At-The-Market Facility Extends cash runway into 2023 ANN ARBOR, Mich. (April 21, 2022) - ENDRA Life Sciences Inc. (NASDAQ
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (March 30, 2022) - ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced
Read more →NDRAENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS System New path developed in consultation with the FDA to include limited confirmatory clinical data and provide potential future competitive
endra_ex991.htm EXHIBIT 99.1 ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS System New path developed in consultation with the FDA to include limited confirmatory clinical data and provide potential future competitive advantages ANN ARBOR, Mich.
Read more →NDRAENDRA Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ndra_ex991.htm EXHIBIT 99.1 ENDRA Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (November 15, 2021) - ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of
Read more →NDRAENDRA Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (August 12, 2021) ENDRA Life Sciences (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound today report
Read more →NDRAENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells ANN A RBOR, Mich. (
ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells ANN ARBOR, Mich. (June 15, 2021) ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ), announced the appointment
Read more →NDRAENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (May 17, 2021) ENDRA Life Sciences (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound today rep
Read more →NDRAENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (
ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (March 25, 2021) ENDRA Life Sciences (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSo
Read more →NDRAENDRA Life Sciences Extends GE Healthcare Collaboration Agreement for Two Y ears Supports Commercialization of TAEUS Ⓡ Product for Imaging NAFLD/NASH to December 2023 ANN ARBOR, MI / ACCESSWIRE /
Sciences Extends GE Healthcare Collaboration Agreement for Two Supports Commercialization of Product for Imaging NAFLD/NASH to ANN ARBOR, MI / ACCESSWIRE / December 21, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSoun
Read more →NDRAENDRA Life Sciences Announces Proposed Public Offering of Common Stock ANN A RBOR , Mich. (
ENDRA Life Sciences Announces Proposed Public Offering of Common ANN ARBOR, Mich. (December 15, 2020) ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, today announced that it intends to offer and sell shares of its common stoc
Read more →NDRAENDRA Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, MI / ACCESSWIRE /
ENDRA Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, MI / ACCESSWIRE / November 16, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acou
Read more →NDRAENDRA Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results ANN ARBOR, MI / ACCESSWIRE /
ENDRA Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results ANN ARBOR, MI / ACCESSWIRE / August 17, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ), today provided a busin
Read more →NDRAENDRA Life Sciences Provides Business Update and Reports First Quarter 2020 Financial Results ANN ARBOR, MI / ACCESSWIRE /
ENDRA Life Sciences Provides Business Update and Reports First Quarter 2020 Financial Results ANN ARBOR, MI / ACCESSWIRE / May 14, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ), today provided a business
Read more →NDRAndra_ex991 ENDRA Life Sciences Announces Cash Strategy and Business Update in Response to COVID-19 ANN ARBOR, MI /
Sciences Announces Cash Strategy and Business Update in Response to ANN ARBOR, MI / April 13, 2020 / ENDRA Life Sciences (NASDAQ: NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound announced a series of proactive measures the company has taken to reduce costs in respon
Read more →NDRAENDRA Life Sciences Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
ENDRA Life Sciences Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results ANN ARBOR, Michigan - March 26, 2020 - ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ: NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ), today provided a
Read more →NDRAENDRA Life Sciences Receives CE Mark for its TAEUS ® Clinical Product Targeting Non-Alcoholic Fatty Liver Disease First regulatory clearance paves the way to commercialize TAEUS in European markets U.S. FDA submissi
Receives CE Mark for its TAEUS Clinical Product Targeting Non-Alcoholic Fatty Liver Disease regulatory clearance paves the way to commercialize TAEUS in U.S. FDA submission expected during H1:20 ANN ARBOR, MI / March 9, 2020/ ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA
Read more →NDRAENDRA Life Sciences Renews GE Healthcare Collaboration Agreement Supports Commercialization of TAEUS Liver Product Targeting NAFLD-NASH ANN ARBOR, MI / ACCESSWIRE /
ENDRA Life Sciences Renews GE Healthcare Collaboration Agreement Supports Commercialization of TAEUS Liver Product Targeting ANN ARBOR, MI / ACCESSWIRE / January 15, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TA
Read more →NDRAENDRA Life Sciences Completes $8.1 Million Private Placement
ENDRA Life Sciences Completes $8.1 Million Private ANN ARBOR, Michigan - December 11, Life Sciences Inc. ( ENDRA ) (NASDAQ:NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ), today announced that it has closed an $8.1 million private placement of its Series A
Read more →NDRAENDRA Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results ● Conference call scheduled for 4:30 p.m. ET today
ENDRA Life Sciences Provides Business Update and Third Quarter 2019 Financial Results Conference call scheduled for 4:30 p.m. ET today ANN ARBOR, Michigan - November 13, 2019 - ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSoun
Read more →NDRAENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants Raise Fortifies Balance Sheet ANN ARBOR, Michigan –
ENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants Raise Fortifies Balance Sheet ANN ARBOR, Michigan July 29, 2019 - ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has
Read more →NDRAENDRA Life Sciences Announces Proposed Public Offering of Common Stock ANN ARBOR, Michigan –
Life Sciences Announces Proposed Public Offering of Common ANN ARBOR, Michigan November 7, 2018 ENDRA Life Sciences Inc. ( ENDRA or the Company ) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, is proposing to offer and sell, subject to market conditions, sh
Read more →NDRAENDRA Life Sciences Inc. Announces Proposed Public Offering of Common Stock ANN ARBOR, Michigan –
ENDRA Life Sciences Inc. Announces Proposed Public Offering of ARBOR, Michigan October 10, 2018 ENDRA Life Sciences Inc. ( ENDRA or the Company ) (NASDAQ: NDRA), a leading developer of photo- and thermo-acoustic technology to bring new capabilities to existing ultrasound sys
Read more →NDRAENDRA Life Sciences Completes Private Placement of $1.1 Million of Convertible Secured Notes and Warrants ENDRA Executive Management Participates to Strengthen the Company's Financial Position Ahead of Key Milestones ANN
ENDRA Life Sciences Completes Private Placement of $1.1 Million of Convertible Secured Notes and Warrants ENDRA Executive Management Participates to Strengthen the Company's Financial Position Ahead of Key ANN ARBOR, Michigan July 2, 2018 - ENDRA Life Sciences Inc. ( ENDRA )
Read more →NDRAENDRA Life Sciences Reports Fourth Quarter and Full Year 2017 Financial Results Management to Host Conference Call Today at 4:30 p.m. EDT ANN ARBOR, Michigan –
ENDRA Life Sciences Reports Fourth Quarter and Full Year Management to Host Conference Call Today at 4:30 p.m. ANN ARBOR, Michigan March 20, 2018 - ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, reported its financial and
Read more →NDRAENDRA Life Sciences Renews and Extends Term of Collaboration Agreement with GE Healthcare to Develop ENDRA's TAEUS™ Clinical Product Targeting Non-Alcoholic Fatty Liver Disease 2018 European Launch Remains on Trac
ENDRA Life Sciences Renews and Extends Term of Agreement with GE Healthcare to Develop ENDRA's TAEUS Product Targeting Non-Alcoholic Fatty Liver Disease 2018 European Launch Remains on Track with Human Data Expected in of 2018 to Support ENDRA's First Commercial Liver ANN AR
Read more →NDRAENDRA Life Sciences Reports Third Quarter 2017 Financial Results Partnerships with Leading Medical Device Developers & Initiation of Human Studies Advance Anticipated 2018 Commercialization of Company's TAEUS™ Fat
ENDRA Life Sciences Reports Third Quarter 2017 Financial Partnerships with Leading Medical Device Developers & Initiation of Human Studies Advance Anticipated 2018 Commercialization of Company's TAEUS Fatty Liver ANN ARBOR, Michigan November 15, 2017 - ENDRA Life Sciences Inc
Read more →NDRAENDRA Life Sciences Announces Separation of Units Sold in IPO Common Stock and Warrants to Trade Separately on The NASDAQ Capital Market Beginning
Life Sciences Announces Separation of Units Sold in Common Stock and Warrants to Trade Separately on The NASDAQ Capital Market Beginning June 28, 2017 ANN ARBOR, Michigan - June 22, 2017 - ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ: NDRAU), a developer of enhanced ultrasound
Read more →Competitive Position
How NDRA ranks across every disease it competes inCompetitive Position is a premium feature
See how NDRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial